Zero Dementia: Building a Multimodal AI Platform for Early Alzheimer's Detection

Alzheimer's disease affects over 55 million people worldwide, and by the time symptoms become clinically apparent, significant neurodegeneration has already occurred. Early detection is the key to intervention — and that's exactly what the Zero Dementia project aims to achieve.

At Biotech Wallah, we built Neuro AI: a multimodal platform that integrates MRI-based image classification with clinical text reasoning in a unified architecture. The system doesn't just look at brain scans — it reads clinical notes, patient histories, and cognitive assessment results alongside the imaging data.

The vision-language fusion approach allows for joint diagnostic prediction and report generation. When the model identifies patterns in an MRI scan, it can cross-reference those findings with textual clinical data to produce a more confident and explainable diagnosis.

Our end-to-end clinical AI workflow covers everything from patient recruitment and data collection to model deployment. This isn't just a research prototype — it's designed for real clinical environments.

The project has been recognized with the Genesis 2.0 Startup Grant (INR 10 Lakh) from the Government of India and the Best Startup of the Year 2025 award from GITM Incubation Center. These validations fuel our mission to make early Alzheimer's detection accessible and affordable.

The next phase involves expanding our dataset through clinical partnerships and refining the multimodal fusion architecture for higher sensitivity in early-stage detection.